The European Commission has approved the cystic fibrosis drug Orkambi® for people with two copies of the F508del mutation ages 12 and older in the European Union.
Site Search
Today, more than 4,000 cystic fibrosis research scientists, clinicians and caregivers are gathering in Phoenix for the 29th Annual North American Cystic Fibrosis Conference (NACFC) in the largest collaborative forum of its kind.
NCQA Honors The Foundation for Leadership in Improving Care
HealthWell to offer co-pay assistance for CF-specific, FDA-approved drugs including prescribed vitamins and supplements.
To the CF Foundation Staff and CF Community: Today, after 35 years with the Cystic Fibrosis Foundation -- and 21 years as president and CEO -- Robert J. Beall, Ph.D., has announced he is stepping down.
Robert J. Beall, Ph.D., today announced he will step down as president and chief executive officer of the Cystic Fibrosis Foundation, effective December 31, 2015. Preston W. Campbell III, M.D., currently the Foundation's executive vice president for medical affairs, will succeed Dr. Beall as president and CEO.
The Cystic Fibrosis Foundation's drug development model, mission and leadership are featured on the front page of The Washington Post today.
Today we received the exciting news that the U.S. Food and Drug Administration has approved Orkambi for people with cystic fibrosis ages 12 and older who have two copies of the F508del gene mutation, the most common CF mutation.
Millions of NASCAR fans will tune in to this Saturday's race at Chicago Speedway, where ARRIS-sponsored driver Daniel Suarez will feature the Cystic Fibrosis Foundation logo on his #18 car.